Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, 85 Park Road, Grafton, Auckland, 1023, New Zealand.
Department of Biochemistry, University of Otago, 710 Cumberland Street, Dunedin, 9012, New Zealand.
Arthritis Res Ther. 2019 Nov 12;21(1):234. doi: 10.1186/s13075-019-2016-6.
Reduced renal clearance of uric acid is a major contributor to hyperuricemia. The aim of this study was to examine clinical and genetic variables associated with fractional excretion of uric acid (FEUA).
Participants (with and without gout) in the Genetics of Gout in Aotearoa study with available genotyping and FEUA data were included (n = 1713). Ten FEUA-associated loci detected within a genome-wide association study for serum urate in a European population were analysed. A polygenic score for FEUA was calculated in each ancestry group to model the cumulative effects of the genetic variants on FEUA. Associations between FEUA and both clinical variables and polygenic score were tested using linear regression models.
The mean (SD) FEUA was 5.13 (2.70) % in Eastern Polynesian participants, 4.70 (5.89) % in Western Polynesian participants, and 5.89 (2.73) % in New Zealand European participants. Although association with FEUA was observed for SLC2A9 rs11942223 in New Zealand European participants (P = 2.39 × 10), this association was not observed in Eastern or Western Polynesian participants. The polygenic score was positively associated with FEUA in all ancestry groups. In New Zealand European participants, body mass index, diuretic use, polygenic score, and male sex were associated with FEUA and explained 22% of FEUA variance in the regression model. In Eastern and Western Polynesian participants, the tested variables explained 10% and 4% of FEUA variance respectively.
Both clinical and genetic variables contribute to renal clearance of uric acid. SLC2A9 exerts effects on FEUA variance in people of European ancestry, but not in those of Polynesian ancestry. There is a large unexplained variance in FEUA, particularly in people of Polynesian ancestry.
尿酸清除率降低是高尿酸血症的主要原因。本研究旨在探讨与尿酸排泄分数(FEUA)相关的临床和遗传变量。
纳入有或无痛风的新西兰痛风遗传学研究中具有可利用基因分型和 FEUA 数据的参与者(n=1713)。分析了在欧洲人群中全基因组关联研究中检测到的与血清尿酸相关的 10 个 FEUA 相关位点。在每个祖先群体中计算 FEUA 的多基因评分,以模拟遗传变异对 FEUA 的累积影响。使用线性回归模型检验 FEUA 与临床变量和多基因评分之间的关联。
东部波利尼西亚参与者的平均(标准差)FEUA 为 5.13(2.70)%,西部波利尼西亚参与者为 4.70(5.89)%,新西兰欧洲参与者为 5.89(2.73)%。尽管在新西兰欧洲参与者中观察到 SLC2A9 rs11942223 与 FEUA 相关(P=2.39×10),但在东部或西部波利尼西亚参与者中未观察到这种关联。多基因评分与所有祖先群体的 FEUA 呈正相关。在新西兰欧洲参与者中,体重指数、利尿剂使用、多基因评分和男性性别与 FEUA 相关,并在回归模型中解释了 FEUA 变异的 22%。在东部和西部波利尼西亚参与者中,测试变量分别解释了 FEUA 变异的 10%和 4%。
临床和遗传变量均有助于尿酸的肾脏清除。SLC2A9 对欧洲血统人群的 FEUA 变异有影响,但对波利尼西亚血统人群没有影响。FEUA 有很大的未解释变异,尤其是在波利尼西亚血统人群中。